2017 Volume 54 Issue 2 Pages 138-142
The standard treatment for B-cell non-Hodgkin Lymphoma (B-NHL) in children consists of short-course highly intensive chemotherapies. However, little is known about how the treatment should be modified for those with acute kidney injury (AKI). Here, we report the case of a one-year-old boy with abdominal Burkitt lymphoma, who presented with severe AKI. We administered rituximab-combined chemotherapy, with methotrexate (MTX) omitted because it is potentially nephrotoxic, in induction therapy. Because of the remarkable tumor reduction and recovery of renal function, the full dosage of MTX was administered with rituximab in the following courses. Complete remission was achieved and no significant adverse events occurred during treatment. His renal function remains normal and he is alive without relapse at one year after the disease onset. The addition of rituximab may be a reasonable choice in treating pediatric B-NHL, when a key cytotoxic drug has to be reduced or omitted owing to severe AKI.
